In terms of immunotyping, CD7 was identified in all patients (18/18) and CD33 in 77.8% (14/18) patients (Table 1 and Figure S1A–F), suggesting that CD7 may serve as the potential diagnostic marker and immunotherapy target especially in non‐T AL. The gene discussed is CD7; the disease is axial length measurement.